TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15945001

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dorzolamide/Timolol fixed combination (DTFC) 0.5%/2%
Number of subjects: 35
Study: 15552533

Group type: EXPERIMENTAL
Intervention: Diet therapy with antihypertensive drugs (E1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Single diet therapy (E2)
Number of subjects: 110
Study: 11208882

Group type: EXPERIMENTAL
Intervention: UVA radiation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: UVB radiation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiotherapy (2 Gy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiotherapy (54 Gy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: p53 and p21 correlation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Erythema (radiation dermatitis)
Number of subjects: 50
Study: 9064058

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily for 3 days
Number of subjects: 421

Group type: COMPARATOR
Intervention: Norfloxacin 800 mg twice daily for 10 days
Number of subjects: 421
Study: 8341188

Group type: EXPERIMENTAL
Intervention: Fixed dose salbutamol (2.5 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Variable dose salbutamol (0.1 mg/kg bodyweight)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both preparations of salbutamol
Number of subjects: 99
Study: 3525883

Group type: EXPERIMENTAL
Intervention: S6472 (1,500 mg/day, 750 mg after breakfast and supper for 14 days)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Cefaclor (CCL) (1,500 mg/day, 500 mg after every meal for 14 days)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Amoxicillin (AMPC) (2,000 mg/day, 500 mg after every meal and at bedtime for 14 days)
Number of subjects: 195
Study: 31236731

Group type: EXPERIMENTAL
Intervention: Tacks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 48
Study: 28849779

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg over 40 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26414893

Group type: EXPERIMENTAL
Intervention: Guided online CBT-I
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Individual face-to-face CBT-I
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list
Number of subjects: 90
Study: 25622633

Group type: EXPERIMENTAL
Intervention: Compound digestive enzyme tablet (Bearse) plus 2 analog capsules of compound digestive enzyme thrice daily
Number of subjects: 203

Group type: COMPARATOR
Intervention: Compound digestive enzyme capsule (Dages) plus 1 analog tablet of compound digestive enzyme thrice daily
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Compound digestive enzyme tablet (Bearse)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Compound digestive enzyme capsule (Dages)
Number of subjects: 203
Study: 23246119

Group type: EXPERIMENTAL
Intervention: Topical voriconazole therapy (1% voriconazole)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrastromal voriconazole (50 μg/0.1 ml)
Number of subjects: 40
Study: 20973308

Group type: EXPERIMENTAL
Intervention: Closed luer-lock access connectors
Number of subjects: 0
Study: 18837860

Group type: EXPERIMENTAL
Intervention: Quetiapine (400-800 mg/day, twice daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 16909881

Group type: EXPERIMENTAL
Intervention: Microgravity environment during parabolic flight
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ground control sessions
Number of subjects: 8
Study: 12482798

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty alone (group 1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Stent placement (group 2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Residual gradient > 10 mm Hg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Residual gradient ≤ 10 mm Hg
Number of subjects: 54
Study: 10096260

Group type: EXPERIMENTAL
Intervention: R-verapamil (120 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7780619

Group type: EXPERIMENTAL
Intervention: rTPA
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Large infarcts
Number of subjects: 104

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 104
Study: 2202889

Group type: EXPERIMENTAL
Intervention: 720-kcal liquid mixed meal (24% protein, 21% fat, 55% carbohydrate)
Number of subjects: 14
Study: 497074

Group type: EXPERIMENTAL
Intervention: Extradural analgesia (EA) with 50 or 100 mg of etidocaine without adrenaline in the supine position
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Extradural analgesia (EA) with 50 or 100 mg of etidocaine without adrenaline in the lateral position
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control period before EA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Decrease in arterial pressure (AP)
Number of subjects: 70
Study: 30049849

Group type: EXPERIMENTAL
Intervention: Vasopressin V2 receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rigorous blood pressure control and various lifestyle and dietary changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring and basic optimized kidney protective measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-modifying treatments (e.g., somatostatin analogs and other novel agents)
Number of subjects: 0
Study: 27283107

Group type: EXPERIMENTAL
Intervention: Urinary catheter removal within 48 hours after operation
Number of subjects: 374

Group type: COMPARATOR
Intervention: Urinary catheter removal 6 hours after epidural catheter removal
Number of subjects: 374
Study: 25332317

Group type: EXPERIMENTAL
Intervention: Intensive low-salt diet education
Number of subjects: 245

Group type: COMPARATOR
Intervention: Conventional low-salt diet education
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study: 21738002

Group type: EXPERIMENTAL
Intervention: Isolated impaired glucose tolerance (i-IGT)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Isolated impaired fasting glucose (i-IFG)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Combined fasting and post-prandial hyperglycemia (IFG/IGT)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Subjects with 2 or more metabolic disorders
Number of subjects: 1869
Study: 19949136

Group type: EXPERIMENTAL
Intervention: Aspirin, 80 mg/d for 8 weeks
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 156
Study: 19034856

Group type: EXPERIMENTAL
Intervention: ATTENTIONER therapy
Number of subjects: 0
Study: 15733716

Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus oral nutritional supplements
Number of subjects: 4023

Group type: COMPARATOR
Intervention: Normal hospital diet
Number of subjects: 4023
Study: 14571284

Group type: EXPERIMENTAL
Intervention: Carbamazepine with honey (200 mg carbamazepine + 30 ml honey)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbamazepine with water (200 mg carbamazepine + water)
Number of subjects: 10
Study: 10356595

Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 346

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Under-reporters
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Dietary intake assessment
Number of subjects: 346
Study: 8618248

Group type: EXPERIMENTAL
Intervention: Extended relief acetaminophen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular release acetaminophen
Number of subjects: 10
Study: 2340539

Group type: COMPARATOR
Intervention: ORS‐90 (WHO ORS) with sodium 90 mmol/L and glucose 111 mmol/L, osmolality 311 mosm/kg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: ORS‐60 with sodium 60 mmol/L and glucose 90 mmol/L, osmolality 240 mosm/kg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both ORS groups
Number of subjects: 130
Study: 7282615

Group type: EXPERIMENTAL
Intervention: Aspartame (34 mg/kg body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sucrose (1 g/kg body weight)
Number of subjects: 6
Study: 6143039

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (after 8 weeks without treatment)
Number of subjects: 29
Study: 31358436

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28340044

Group type: EXPERIMENTAL
Intervention: MK-0677
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 27328752

Group type: EXPERIMENTAL
Intervention: Naltrexone/bupropion (NB) 32/360 mg
Number of subjects: 2043

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2043
Study: 24251424

Group type: EXPERIMENTAL
Intervention: Nutritional supplement drinks served in a glass/beaker
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nutritional supplement drinks served via straw
Number of subjects: 45
Study: 22568178

Group type: EXPERIMENTAL
Intervention: Subjects with carbohydrate disorders
Number of subjects: 112

Group type: COMPARATOR
Intervention: Comparative group without cardiovascular diseases and carbohydrate disorders
Number of subjects: 112
Study: 20200540

Group type: EXPERIMENTAL
Intervention: Multinutrient supplement providing increased protein and energy (P/E)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Energy supplementation alone (medium chain triglyceride oil, MCT)
Number of subjects: 23
Study: 17638495

Group type: EXPERIMENTAL
Intervention: Positive display rules (e.g., be enthusiastic and hide frustration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Display autonomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Customer hostility during one of the calls
Number of subjects: 0
Study: 15947510

Group type: EXPERIMENTAL
Intervention: Exposure to related cues
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Exposure to related and other cues followed by well-being therapy (WBT)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Well-being therapy (WBT)
Number of subjects: 3
Study: 12233989

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MTP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10102254

Group type: EXPERIMENTAL
Intervention: Weight loss of 11.7% ± 2.8% at 8 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Weight loss of 20.1% ± 7.0% at 48 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Weight loss maintained at week 100
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Weight gain of 7.4 ± 7.4 kg from weeks 48 to 100
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol
Number of subjects: 25
Study: 7597439

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (doses escalated from 300 to 450 mg/m2 for carboplatin and 125 to 175 mg/m2 for paclitaxel)
Number of subjects: 14
Study: 2113764

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (15 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg, 3 times daily)
Number of subjects: 20
Study: 288389

Group type: EXPERIMENTAL
Intervention: Factor VIII concentrate (30 units/kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Prothrombin-complex concentrate (Prothrombinex, 30 units of factor IX/kg)
Number of subjects: 4
Study: 30584782

Group type: EXPERIMENTAL
Intervention: Combination therapy (CT; multimodal therapy plus aerobic training)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Multimodal therapy (MT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 126
Study: 28121280

Group type: EXPERIMENTAL
Intervention: Survey and education pamphlet (intervention group)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Survey only (control group)
Number of subjects: 237
Study: 27490162

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 µg
Number of subjects: 2356

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 µg
Number of subjects: 2356

Group type: COMPARATOR
Intervention: HandiHaler 18 µg
Number of subjects: 2356
Study: 23748157

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing
Number of subjects: 811

Group type: COMPARATOR
Intervention: Laboratory testing (Control)
Number of subjects: 811
Study: 22155531

Group type: EXPERIMENTAL
Intervention: Self-regulatory intervention (SRI) focused on self-monitoring of spontaneous physical activity (SPA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Weight loss intervention without self-regulatory behavioral strategy
Number of subjects: 72
Study: 19197174

Group type: EXPERIMENTAL
Intervention: Couple-based interventions that educate both partners about the woman's diagnosis and treatments, promote mutual coping and support, and include sexual therapy techniques.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Couple-focused interventions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Interventions including sexual therapy techniques
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Future interventions should include measures of body image, sexual satisfaction, and sexual dysfunction.
Number of subjects: 12
Study: 17203016

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acute VNS
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: VNS therapy
Number of subjects: 9
Study: 15206991

Group type: EXPERIMENTAL
Intervention: Terbogrel 150 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Terbogrel 50 mg, 100 mg, 150 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 330 mg once-a-day
Number of subjects: 48
Study: 11143737

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg or ibuprofen 400 mg
Number of subjects: 6
Study: 9360028

Group type: EXPERIMENTAL
Intervention: 500 mg/day ASA at Time 2 (7h to 9h after awakening)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA at Time 3 (within 2h of bedtime)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA at Time 2 (7h to 9h after awakening)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA for hypertensive patients at Time 2 (7h to 9h after awakening)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA for hypertensive patients at Time 3 (within 2h of bedtime)
Number of subjects: 91
Study: 8473961

Group type: EXPERIMENTAL
Intervention: Coached on symptoms of schizophrenia
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Coached on strategies for the detection of fakers
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Coached on both symptoms and strategies
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Uncoached
Number of subjects: 72

Group type: COMPARATOR
Intervention: Honest condition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Schizophrenic inpatients
Number of subjects: 72
Study: 3009050

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of beta-blockers (group 1)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo treatment (group 1)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Continuation of beta-blockade therapy (group 4)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Withdrawal of beta-blockade (group 3)
Number of subjects: 326
Study: 29126270

Group type: EXPERIMENTAL
Intervention: Maximal Strength Training (MST)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 23
Study: 28478138

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training (ABMT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo Training (PT)
Number of subjects: 29
Study: 25028177

Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Antiarrhythmic Drug Therapy (ADT)
Number of subjects: 146
Study: 23411788

Group type: EXPERIMENTAL
Intervention: High-efficiency postdilution online hemodiafiltration (OL-HDF)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 906
Study: 21667142

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention in 12 communities
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control communities (12 communities)
Number of subjects: 24
Study: 18486752

Group type: EXPERIMENTAL
Intervention: Collaborative testing (experimental group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Individualistic testing (control group)
Number of subjects: 114
Study: 16516074

Group type: EXPERIMENTAL
Intervention: Abciximab-coated stents (group I)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bare metal control stents (group II)
Number of subjects: 96
Study: 12937228

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Amlodipine (5 mg daily)
Number of subjects: 97
Study: 11201622

Group type: EXPERIMENTAL
Intervention: Isometric muscle strength in knee extensors and flexors
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Isokinetic muscle strength at 60 degrees/s and 180 degrees/s in knee extensors and flexors
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Dynamic and static endurance of knee extensors
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Isometric strength in ankle plantar and dorsiflexor muscles
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Isokinetic ankle plantar flexion strength at 60 degrees/s with and without prior eccentric contraction
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Hand-grip strength evaluated with a dynamometer
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Walking velocity and number of heel-rises
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Muscle biopsies from vastus lateralis muscle for histochemical and enzymatic analyses
Number of subjects: 144
Study: 9180836

Group type: EXPERIMENTAL
Intervention: Ifosfamide 15 g/m2/cycle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ifosfamide 3 g/m2 during 5 days
Number of subjects: 10
Study: 1587761

Group type: EXPERIMENTAL
Intervention: Twice-a-day radiation therapy (hyperfractionation) delivering 120 cGy per fraction, two fractions a day for a total of 6000 cGy in 50 fractions over 5 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional fractionation delivering 200 cGy per fraction for a total of 5000 cGy in 25 fractions over 5 weeks
Number of subjects: 30
Study: 3929934

Group type: EXPERIMENTAL
Intervention: Paediatric endoscopic forceps biopsy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard endoscopic forceps biopsy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Duodenal capsule biopsy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Jejunal capsule biopsy
Number of subjects: 40
Study: 31667062

Group type: EXPERIMENTAL
Intervention: Saracatinib 125 mg/day for 28 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29925849

Group type: EXPERIMENTAL
Intervention: Spatial bisection task
Number of subjects: 23

Group type: COMPARATOR
Intervention: Minimum audible angle (MAA) task
Number of subjects: 23

Group type: COMPARATOR
Intervention: Temporal bisection task
Number of subjects: 23
Study: 27755159

Group type: EXPERIMENTAL
Intervention: Peony-Glycyrrhiza Decoction (PGD) 45 g/d for 16 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 24148194

Group type: EXPERIMENTAL
Intervention: GH (30 ng × kg(‐1) × min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fasting (36 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 23735317

Group type: EXPERIMENTAL
Intervention: Aloe QDM complex
Number of subjects: 136
Study: 20542963

Group type: EXPERIMENTAL
Intervention: Modified-release (MR) prednisone (2-10 mg/day)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Immediate-release (IR) prednisone
Number of subjects: 288

Group type: COMPARATOR
Intervention: Both MR and IR groups
Number of subjects: 288
Study: 19288904

Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion
Number of subjects: 209

Group type: COMPARATOR
Intervention: Yueyue Shu Granules (control)
Number of subjects: 209
Study: 17054466

Group type: EXPERIMENTAL
Intervention: Raloxifene (180 mg/day) + Oestradiol (100 microg/24 h for last 10 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clomiphene (150 mg/day) + Oestradiol (100 microg/24 h for last 10 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oestradiol (100 microg/24 h for 30 days) + Raloxifene (180 mg/day for last 10 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oestradiol (100 microg/24 h for 30 days) + Clomiphene (150 mg/day for last 10 days)
Number of subjects: 16
Study: 12576315

Group type: EXPERIMENTAL
Intervention: 600 mg BIRB 796 BS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 mg BIRB 796 BS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10720290

Group type: EXPERIMENTAL
Intervention: Classic T2-hyperintense lesion along the ipsilateral corticospinal tract observed in patients with MS
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Initial inciting event located in the white matter of the superior aspect of the corona radiata
Number of subjects: 5
Study: 7933324

Group type: EXPERIMENTAL
Intervention: Diphtheria and tetanus toxoid vaccine (DT) primed infants given PRP-T
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Diphtheria and tetanus toxoid vaccine (DT) primed infants given HbOC
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (unprimed infants) given PRP-T or HbOC
Number of subjects: 94
Study: 3064604

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 29520889

Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 600 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100